There is now evidence that the rules established for tumor immunology and immunotherapy in general are relevant for brain tumors. Treatment strategies explored have mainly involved vaccines using either tumor cells or components, and vaccines with defined synthetic peptides. This latter approach offers the advantage to select well-characterized antigens with selective or preferential expression on glioma. This is a prerequisite because collateral damage to the brain is not allowed. A second strategy which is reaching clinical trials is T cell therapy using the patients' own lymphocytes engineered to become tumor reactive. Tumor specificity can be conferred by forced expression of either a high-avidity T cell receptor or an antitumor antibody (the latter cells are called chimeric antigen receptors). An advantage of T cell engineering is the possibility to modify the cells to augment cellular activation, in vivo persistence and resistance to the tumor immunosuppressive milieu. A direct targeting of the hostile glioma microenvironment will additionally be required for achieving potent immunotherapy and various trials are assessing this issue. Finally, combining immunotherapy with immune checkpoint inhibitors and chemotherapy must be explored within rigorous clinical trials that favor constant interactions between the bench and bedside. Regarding immunotherapy for glioma patients, what was an unrealistic dream a decade ago is today a credible prospect.
M ore than 50 years ago, the concept of tumor immune surveillance was postulated by Burnet and Thomas with the dream to exploit this natural property for treating cancers. After several waves of skepticism and hope, targeting cancer cells with immune effectors is not only considered as just a promising strategy, but as a real treatment option with remarkable benefıt for some patients with melanoma, kidney cancer or leukemia/lymphoma. 1 What about glioma? Can immune based treatments be developed for tumors located in the brain? For several decades, this question was neglected based on the observation that the brain was tolerant for some xenogeneic or allogeneic tissues that were rejected when implanted outside the central nervous system. But we progressively learned that the immune privileged status of the brain is not absolute but relative, with cumulative experimental and clinical evidence that T cells may enter the brain and kill glioma cells. 2 Glioma immunotherapy research has also been slowed down by other obstacles, that is, the paucity of well-characterized glioma antigens and the intrinsic risk of collateral damage to normal structures and functions. Although some level of autoimmune attack could be allowed for skin or prostate cancers, this is obviously not the case for an organ as delicate and essential as the brain. The recent discovery of antigens with selective or preferential expression by glioma cells [3] [4] [5] is opening the hope of targeting tumor cells while preserving normal cells. However, are such conceptual advances fostering illusion or creating realistic and promising prospects? In other words, will current strategies developed for brain tumors follow the same rules as for tumors outside the brain, and with which therapeutic potential?
ANTITUMOR IMMUNE RESPONSES WITHIN AND OUTSIDE THE BRAIN: THE SAME RULES?
The current knowledge of a spontaneous antitumor response is briefly illustrated in Fig. 1 . Tumor cells are recognized as a danger and captured by the antigen presenting cells (APCs), mostly dendritic cells (DCs). Then DCs migrate via lymphatic vessels to draining lymph nodes, acquiring costimulation properties. There, DCs present tumor-derived peptides to T cells and activate them. As a consequence, T cells clonally expand and are imprinted with homing phenotypes favoring their traffıc to the tumor-involved organs. T cells are the main effector cells of the antitumor immune response, exhibiting homing, recognition, killing, and memory properties. Does the same model apply for tumors in the brain? The answer is not intuitively yes in an organ in which APCs are not well defıned, lymphatic vessels are not detected in the brain parenchyma, and in which the traffıcking of immune cells is regulated by the blood-brain barrier. However, despite some unresolved issues (e.g., the precise identity of APCs able to transport tumor antigen to cervical lymph nodes), there is now cumulative evidence that the model presented in Fig. 1 is also relevant for brain tumors. Therefore, it can be used to represent the different approaches of glioma immunotherapy: (1) therapeutic vaccines for activation of T cells in vivo, (2) adoptive immunotherapy with T cells engineered ex vivo, and (3) various strategies for reversing glioma-related immunosuppression.
VACCINES
Two main strategies have emerged for activating effector T cells in vivo, using either tumor cell-based vaccines or molecularly defıned antigens.
Tumor Cell-Based Vaccines
Tumor cell-based vaccines are mostly autologous DCs pulsed with whole glioma lysates, eluted peptides, tumor RNA, or fusions of DCs and glioma cells. The main advantage of this approach is to provide a very large amount of tumor antigens including private epitopes present in individual gliomas. However, although interesting survival data have been reported in phase II trials, 6 there are several possible drawbacks limiting the further development of tumor cell-based vaccines in glioma. The production of cells is labor intensive and expensive, with many challenges in manufacturing and generating cells with reproducible characteristics. In addition, vaccine effıcacy is mainly assessed by the level and the quality of the induced immune responses (as measured by immunomonitoring). In the case of tumor lysates, the antigens are undefıned, which strongly limits the immunomonitoring-driven optimization of the vaccine schedule, dose, or composition. The main concern is the autoimmune damages induced by immune responses against antigens shared by normal and tumor cells and/or expressed by normal cells contaminating tumor cell preparations. Curiously, this has not been observed to date. Whether this means that a therapeutic window may be found, or whether the lack of autoimmunity reflects a level of immune response under the threshold of effıcacy to eliminate tumor cells, is presently unknown. A single phase III trial is ongoing to address this question (NCT00045968), but has a low accrual rate, illustrating the complexity of this approach.
Defined Peptides
Important advantages of vaccines with synthetic peptides are that glioma tissue is not required for the vaccine and that they
KEY POINTS
⅐ Multipeptide vaccines and cell therapy with engineered T lymphocytes are promising strategies for patients with glioma. ⅐ The selection of antigens targeted by immune effectors must be extremely rigorous to avoid unacceptable damage in the context of the brain. ⅐ Reshaping the brain tumor microenvironment is required to ensure optimal efficacy of immune effector cells. ⅐ Emerging data indicate that synergies with immune checkpoint inhibitors and chemotherapy must be exploited. ⅐ Multiples challenges remain, but using the immune system to fight glioma is now a realistic prospect. should be at a lower risk of inducing autoimmunity (at least with well selected peptides). The results obtained over the last decade with several antigen candidates (EphA2, IL-13R␣2, YKL-40, gp100, survivin, TRP-2, MAGE-1, AIM-2, and HER2) in phase I/II trials have recently been reported in excellent reviews [7] [8] [9] and ongoing studies are presented in Table  1 . Overall, vaccination with these antigens was shown to be safe and immunogenic with antigen-specifıc immune responses induced in the blood and sometimes in the tumor bed. Some preliminary observations also suggest a potential clinical activity with prolonged survival compared with historic cohorts, although the inevitable bias of inclusion of patients with a good prognosis in early phases of clinical development makes such data diffıcult to interpret. But the main concern is perhaps that most antigens do not necessarily meet all the stringent criteria for an ideal antigen in the context of tumors located in the brain (i.e., confırmed expression of protein in vivo as well as in cell lines, wide expression by tumor cells and many patients, little or no expression by normal tissues to avoid central or peripheral deletion of specifıc T cells, or the risk of autoimmune damage). The identifıcation of ideal antigens is therefore a critical and challenging issue for brain tumors. This way was paved by the discovery that glioblastoma may express a truncated form of epidermal growth factor receptor (EGFR), called EGFRvIII. 3 This is a truly tumor-specifıc tumor antigen expressed by glioma cells and not by normal cells. Based on promising clinical and immunologic data obtained in a phase II study with a 14-amino acid peptide coupled to a "helper molecule" (PEPvIII or rindopepimut), 10 a randomized phase III trial is ongoing with excellent accrual (this part is covered by PR Lowenstein).
More recently, Dutoit et al used an elegant peptide-elution approach to identify tumor-specifıc antigens expressed by a majority of glioma in vivo. 5 Briefly, from 3686 HLA-A2 restricted peptides eluted from 32 human glioma samples, 10 were selected based on the following criteria: (1) high ratio of mRNA expression in glioma versus normal tissues, (2) expression by at least 70% of samples, (3) glioma-associated function of the related protein, and (4) immunogenicity of the peptides in healthy donors. The choice of the 10 peptides was then validated by major histocompatibility complex (MHC)-peptide quantifıcation in in vivo samples, immunohistochemistry of a series of 250 human glioblastoma, and by testing the immunogenicity of the peptides in patients with glioblastoma. Strong and multiantigenic immune responses were observed for most patients with glioblastoma in vitro, with CD8 ϩ T cell clones exhibiting specifıc lysis of glioma cells. This set of MHC class I-binding peptides plus two MHC class II-binding peptides (IMA 950) is now under investigation in three clinical trials (Table 1) . This vaccine has the advantage to target antigens with confırmed in vivo expression, to diversify the immune responses against several antigens (see immunoediting below), and to stimulate CD4 T cells against tumor-expressed antigens to promote antitumor activity. 11
The Need for Efficient Adjuvants
In contrast to infectious agents, tumor-derived peptides do not include pathogen-associated molecular patterns (PAMP), and thus, the use of adjuvants to stimulate innate immunity and achieve a high magnitude antigen-specifıc response seems mandatory. 12 Encouraging results have been reported with Toll-like receptor (TLR) agonists (TLR-9 agonist CpG, TLR-7 agonist imiquimod, TLR-3 and MDA-5 agonist poly-IC). Although there are no comparative studies, poly-ICLC (Hiltonol) is a particularly attractive compound because of its potential to directly act on the brain tumor microenvironment and its capacity to promote the induction of glioma-specifıc T cells expressing homing molecules favoring brain entry. 13 
ENGINEERED T CELLS
T cell adoptive therapy for cancer treatment can be defıned as the transfer of tumor-specifıc T cells, previously selected and expanded ex vivo. T cell therapy began with the expansion of tumor infıltrating lymphocytes that were shown to contain high numbers of tumor-specifıc T cells. 14 However, this approach is time and labor consuming and requires highly immunogenic, large, and accessible tumors. Moreover, T cells present at the tumor bed are often exhausted limiting their functions, their proliferative capacity, and their persistence after infusion in patients.
Therefore, other means of using the patient's own T cells to target the tumor have been developed. Instead of starting with T cells isolated from the tumor bed, peripheral blood T lymphocytes are being used and modifıed by genetic engineering to provide them with tumor specifıcity. There are two ways such tumor specifıcity can be conferred 14 (Fig. 2) . The fırst is the expression of a high-affınity T cell receptor (TCR) specifıc for a tumor antigen. These high-affınity TCRs can be isolated from patient T cells displaying spontaneous or vaccine-induced effıcient antitumor responses, or they can be generated by modifıcation of the TCR antigen binding region to increase avidity of tumor-specifıc T cells. This approach is poorly explored to date for brain tumors, since glioma-specifıc T cell clones are extremely diffıcult to generate.
The second approach is to force expression of an antitumor antibody at the surface of T cells. The antibody is linked by molecular engineering to the T cell activation pathway, thereby redirecting the T cell killing functions to tumor cells. This strategy, using the so-called chimeric antigen receptors (CARs), has the advantage to bypass recognition through the MHC complex, being therefore applicable to all patients irrespective of their MHC alleles expressed, and most importantly, hampering tumor evasion through MHC downmodulation. An additional advantage of T cell engineering is the possibility to generate T cells with optimal effıcacy in vivo by increasing activation, in vivo persistence, and resistance to the immunosuppressive tumor microenvironment. In CAR T cells, this is mainly achieved through addition of costimu- latory molecules in the CAR construct and through carefully chosen culture conditions. CAR T cells were recently shown to be extremely effıcient for the treatment of resistant chronic and acute leukemia. 15 Whether similar results would be obtained in the future for glioma is diffıcult to predict. Indeed, to date, the application of engineered T cell therapy for the treatment of human glioma has been limited by the paucity of glioma antigens for which expression profıles in normal tissues is well characterized. This is a crucial point in the brain, considering the risk Abbreviations: GM-CSF, granulocyte macrophage colony-stimulating factor; GBM, glioblastoma; AA, anaplastic astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma; KLH, keyhole limpet hemocyanin; VEGF, vascular endothelial growth factor; A, astrocytoma; GAA, glioma associated antigen; BTIC, brain tumor initiating cell; DPIG, diffuse intrinsic pontine glioma; BTSC, brain tumor stem cell; DC, dendritic cell; CMV, cytomegalovirus; ALT, autologous T cell transfer; BSG, brainstem glioma.
IMMUNOTHERAPY FOR GLIOMA asco.org/edbook | 2014 ASCO EDUCATIONAL BOOKof severe toxicity (including death) induced by very effıcient CARs targeting antigens expressed at very low levels on normal cells. 16 This is probably the main reason why only two clinical trials with CAR T cells are currently ongoing, targeting either the HER2 molecule or the EGFRvIII protein (NCT01454596 and NCT01109095, respectively). Nevertheless, the recent identifıcation of several glioma-associated antigens and availability of glioma-specifıc T cell clones 5 opens the possibility to design both novel glioma-specifıc CARs and TCR-engineered T cells for future clinical application.
RESHAPING THE HOSTILE GLIOMA MICROENVIRONMENT
When designing immune-based strategies for fıghting brain tumors, one should never forget that glioma is THE expert in immune escape. Transforming growth factor-beta (TGF-␤) was fırst discovered in glioma supernatant three decades ago. 17 This was the fırst mechanism of immune evasion in a long list of subterfuges used by glioma to counterattack im- . 18 To date, most clinical endeavors to reverse local immunosuppression have focused on TGF-␤ -using monoclonal antibodies, TGF-␤2-specifıc antisense oligo-deoxynucleotide or TGF-␤R kinase inhibitor-and Tregs-monoclonal antibodies targeting Treg receptors (e.g., CD25, CTLA-4), molecules involved in Treg traffıcking and recruitment to tumor bed (CCR4), or systemic chemotherapy (e.g., cyclophosphamide, temozolomide). 18 One of the main questions is to defıne the hierarchy of all mechanisms of immune evasion and to investigate whether the inhibition of one of them could tilt the balance in favor of effective immune response. Although fırst results obtained with the approach of reversing immunosuppression are rather disappointing when used alone, this strategy should not be abandoned and is more likely to provide some benefıt in combination with vaccines and T cell therapy.
CHALLENGES AND OPPORTUNITIES Anatomic Constraints and Steroids
The development of immunotherapy for brain tumors is arguably more challenging than for tumors outside of the brain. Not only is even a slight level of autoimmunity not tolerable, but specifıc anatomic constraints are also present (i.e., the rigid skull). Therefore, any inflammation or edema induced by the tumor or immune cells is likely to induce severe signs and symptoms which are best alleviated by steroids. The lympholytic properties of steroids are well established and a substitute of cortisone will be more than welcome in this situation. Recent data with corticorelin acetate are encouraging but further research is warranted. 19 
The Need for Animal Models
Based on current knowledge, a huge amount of treatment combinations should be tested. This is not possible in humans and we need a tool for a fırst selection. However, human xenografts in immunosuppressed mice are probably not the best models to explore the potential of immune-based treatments. Syngeneic mouse models can provide useful data if correctly interpreted, but direct extrapolation to humans will rarely be possible. Continued development of mice with humanized immune systems may offer additional opportunities for breaching the mouse-to-human translational gap.
Where Should Immunotherapy Be Delivered?
Most current trials are investigating vaccines injected subcutaneously, intradermally or even intranodally, and T cells are infused in the blood. However, immunogens delivered in the tumor bed may favor the imprinting of T cells with brain homing. 20 Moreover the depletion of tumor-specifıc Tregs in a single tumor site (using CTLA-4 and OX40 monoclonal antibodies) was recently shown to mediate a systemic immune response leading to the eradication of disseminated tumors, including in the brain. 21 Thus, should we combine local (intratumoral) and systemic immune manipulation, as suggested by vom Berg et al 22 in a model showing impressive effıcacy of the combination of intratumoral IL-12 delivery and systemic blockade of CTLA-4? This is an exciting option to be further explored.
Immune Checkpoints
Blocking immune checkpoints during activation (cytotoxic T-lymphocyte antigen 4 [CTLA-4]) and effector (programmed cell death 1 [PD-1]) phases was shown to be a highly effective strategy in melanoma and some other solid tumors. This obviously has to be explored in human glioma as well (NCT01952769). Targeting PD-1/PD-ligand (L)1 interaction is particularly attractive, considering PD-L1 expression by a high percentage of primary tumors and CD133 ϩ glioblastoma stem cells. 23 Theoretically, the combination of monoclonal antibodies against CTLA-4 and PD-L1 (or PD1) may promote a sustained immune response, target tumor cells and cancer stem cells, and deplete Tregs.
Immunoediting and Epitope Spreading
In the phase II study investigating rindopepimut, Sampson et al reported that recurrent glioblastoma had lost the antigen (EGFRvIII) targeted by immunization, suggesting that the induced immune response may remodel expressed tumor antigens. 10 This is a very important observation supporting the concept of immunoediting in cancer immunotherapy, and demonstrating the need to target several antigens and, in the future, to adapt the immune effectors against modifıed tumor cells, similarly to what is currently done with tyrosine kinase inhibitors. Another area to further explore is how to promote epitope spreading. The same authors recently observed in a model that mice with EGFRvIII-expressing glioma successfully treated with EGFRvIII CAR T cells developed immunity against tumor antigen loss variants. 24 
Combination with Chemotherapy
Now that promising glioma immunotherapies are reaching clinical trial, a major challenge is how to combine them with chemotherapy or targeted therapies. Emerging data indicate that compatibilities and even synergies are possible. Anticancer agents can positively affect immunotherapies by augmenting immune activation, by rendering tumor cells more visible or sensitive to immune cells, and by favoring recruitment of effector cells rather than immunosuppressive cells to the tumor bed. 25, 26 Paradoxically, myeloablation or leukodepletion occurring as a side effect of chemoradiotherapy agents can actually be complementary or even synergistic with some immunotherapies. One mechanism is that immunosuppressive Tregs are preferentially depleted, as most clearly demonstrated with low dose, metetronomic cyclophosphamide. 27 In the context of glioma, temozolomide is myelosuppressive and induces at least transient lymphopenia, but evidence for Treg depletion is still equivocal. [28] [29] [30] An additional mechanism favoring compatibility with T-cell-mediated immunotherapy is enhanced homeostatic lymphocyte proliferation of vaccine-induced or adoptively transferred T cells in lymphopenic patients. For instance, in a recent EGFRvIII targeting vaccination trial, glioma-specifıc immune responses were positively correlated with the degree of lymphodepletion by dose-intensifıed temozolomide. 28 Determining the minimum number of lymphocytes compatible with vaccination will undoubtedly aid the design of successful treatment protocols for future trials.
CONCLUDING REMARKS
In the future, will we be using the immune system to effı-ciently treat patients with glioma? The answer was no a few decades ago, and even 10 years ago it was an unrealistic dream. But today, it is a credible prospect for the future thanks to the progressive integration of advances in cancer biology and immunology into the clinical arena. We now have rationally designed immunotherapies for clinical testing. Among the important obstacles and challenges remaining are how to optimally use these new therapies along with existing treatment modalities, and how to monitor both immunologic and clinical outcome. We look forward to seeing these issues addressed in rigorous clinical trials that favor constant interactions between bench and bedside.
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